This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_MELANOMA_EXALLC for full statistics.
Malignant melanoma
C3_MELANOMA
No definition available.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
Primary healthcare outpatient: ICD-10:
C51.03&, C51.13&, C51.23&, C51.82&, C52.93&, C69.02&, C69.82&, C69.92&, D03.9&
Hospital Discharge: ICD-10
C51.03&, C51.13&, C51.23&, C51.82&, C52.93&, C69.02&, C69.82&, C69.92&, D03.9&
Cause of death: ICD-10
C51.03&, C51.13&, C51.23&, C51.82&, C52.93&, C69.02&, C69.82&, C69.92&, D03.9&
Cancer registry: Topography ICD-O-3
ANY
Cancer registry: Morphology ICD-O-3
877[0-4]
Cancer registry: Behaviour codes
3
4 out of 7 registries used, show all original rules.
137
Check minimum number of events None
137
Remove individuals based on genotype QC
3960
C3_MELANOMA
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF9
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Malignant melanoma
based on the number of shared cases.
Broader endpoints:
- Malignant melanoma (controls excluding all cancers)
- Any event in hilmo or specialist outpatient
- Any ICDMAIN event in hilmo or causes of death
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3960 | 1947 | 2013 |
| Unadjusted prevalence (%) | 1.05 | 0.92 | 1.21 |
| Mean age at first event (years) | 61.30 | 57.98 | 64.52 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_MELANOMA – Malignant melanoma
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Malignant melanoma
↥Endpoint not on priority list, no data to show.